Athersys Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
31,948.00
26,127.00
23,027.00
14,753.00
29,316.00
51,059
Total Accounts Receivable
520.00
694.00
361.00
598.00
739.00
4,990
Other Current Assets
387.00
427.00
429.00
929.00
1,135.00
1,791
Total Current Assets
32,855.00
27,248.00
23,817.00
16,280.00
31,190.00
57,840
Net Property, Plant & Equipment
1,333.00
1,270.00
1,135.00
2,605.00
2,206.00
3,002
Other Assets
-
-
-
-
197.00
888
Total Assets
34,188.00
28,718.00
25,129.00
19,060.00
33,593.00
61,730
ST Debt & Current Portion LT Debt
-
-
166.00
-
-
Accounts Payable
2,243.00
2,767.00
2,702.00
4,761.00
4,469.00
Other Current Liabilities
2,125.00
1,925.00
1,888.00
2,114.00
5,614.00
Total Current Liabilities
4,368.00
4,692.00
4,756.00
6,875.00
10,083.00
Long-Term Debt
176.00
183.00
-
-
-
Deferred Taxes
-
200.00
177.00
175.00
-
Other Liabilities
9,823.00
2,948.00
649.00
1,004.00
134.00
Total Liabilities
14,367.00
7,823.00
5,405.00
7,879.00
10,217.00
Common Equity (Total)
19,821.00
20,895.00
19,724.00
11,181.00
23,376.00
Total Shareholders' Equity
19,821.00
20,895.00
19,724.00
11,181.00
23,376.00
Total Equity
19,821.00
20,895.00
19,724.00
11,181.00
23,376.00
Liabilities & Shareholders' Equity
34,188.00
28,718.00
25,129.00
19,060.00
33,593.00

About Athersys

View Profile
Address
3201 Carnegie Avenue
Cleveland Ohio 44115
United States
Employees -
Website http://www.athersys.com
Updated 07/08/2019
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J.